Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases
Anne Jacobson
Abstract
In the phase III DESTINY-Breast03 trial, trastuzumab deruxtecan improved progression-free survival (PFS) relative to trastuzumab emtansine across all patients with HER2-positive metastatic breast cancer, including a 75% improvement in PFS among those with baseline brain metastases.
Topics & Concepts
MedicineTrastuzumabMetastatic breast cancerOncologyTrastuzumab emtansineInternal medicineBreast cancerProgression-free survivalBrain metastasisCancerOverall survivalMetastasisBrain Metastases and TreatmentCancer Treatment and PharmacologyRadiopharmaceutical Chemistry and Applications